Attached files

file filename
EX-23.1 - EXHIBIT 23.1 - MAXCYTE, INC.tm2113965d14_ex23-1.htm
EX-5.1 - EXHIBIT 5.1 - MAXCYTE, INC.tm2113965d14_ex5-1.htm

 

As filed with the Securities and Exchange Commission on July 29, 2021

Registration No. 333-  

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM S-1

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

 

MaxCyte, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware
(State or other jurisdiction of incorporation or
organization)
  8731
(Primary Standard Industrial
Classification Code Number)
  52-2210438
(I.R.S. Employer
Identification No.)

 

22 Firstfield Road, Suite 110

Gaithersburg, Maryland 20878

(Address, including zip code, and telephone number, including

area code, of registrant’s principal executive offices)

 

 

 

Doug Doerfler

President and Chief Executive Officer

MaxCyte, Inc.

22 Firstfield Road, Suite 110

Gaithersburg, Maryland 20878

(301) 944-1700

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

Copies to:
 

Brian F. Leaf

Christian E. Plaza

Katie A. Kazem

Cooley LLP

One Freedom Square

Reston Town Center

11951 Freedom Drive

Reston, Virgina 20190

(703) 456-8000

Maher Masoud

EVP and General Counsel

MaxCyte, Inc.

22 Firstfield Road, Suite 110

Gaithersburg, Maryland 20878

(301) 944-1700

Michael D. Maline

Patrick O’Malley

Kathryn Fortin

DLA Piper LLP (US)

1251 Avenue of the Americas

New York, New York 10020

(212) 335-4500

 

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ¨

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x (333-257810)

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨   Accelerated filer ¨   Non-accelerated filer x   Smaller reporting company ¨¨
        (Do not check if a
smaller reporting company)
   
Emerging growth company x            
             

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. x

 

 

 

CALCULATION OF REGISTRATION FEE

 

 

 

Title of Securities

to be Registered 

Amount to be
Registered(1)

Proposed

Maximum
Offering Price
Per Share(2)(3)

Proposed

Maximum
Aggregate
Offering Price(3)

Amount of
Registration

Fee(3)

Common stock, par value $0.01 per share 1,725,000 $13.00 $22,425,000 $2,446.57
 
(1) Represents only the number of shares being registered pursuant to this Registration Statement, which includes 225,000 shares that the underwriters have the option to purchase to cover over-allotments and are in addition to the 13,800,000 shares that were registered pursuant to the Registrant’s Registration Statement on Form S-1 (File No. 333-257810), which included 1,800,000 shares that the underwriters have the option to purchase to cover over-allotments.
(2) Based on the public offering price.
(3) The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant previously registered securities at an aggregate offering price not to exceed $13.50 on a Registration Statement on Form S-1 (File No. 333-257810), which was declared effective by the Securities and Exchange Commission on July 29, 2021. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $22,425,000 is hereby registered, which includes shares issuable upon the exercise of the underwriters’ option to purchase additional shares.

 

 

 

The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.

 

 

 

 

 

 

EXPLANATORY NOTE AND

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

 

This Registration Statement (the “Registration Statement”) is being filed with the Securities and Exchange Commission (the “Commission”) with respect to the registration of additional shares of common stock, par value $0.01 per share, of MaxCyte, Inc. (the “Registrant”), pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Securities Act”). This Registration Statement incorporates by reference the contents of, including all amendments and exhibits thereto, the Registration Statement on Form S-1, as amended (File No. 333-257810) (the “Prior Registration Statement”), which the Commission declared effective on July 29, 2021, and is being filed solely for the purpose of increasing the number of shares to be offered in the public offering by 1,725,000 shares, including 225,000 shares that may be sold pursuant to the underwriters’ option to purchase additional shares. The additional shares that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Prior Registration Statement.

 

EXHIBIT INDEX

 

Exhibit
Number
  Description
5.1   Opinion of Cooley LLP as to legality.
     
23.1   Consent of CohnReznick LLP, independent registered public accounting firm.
     
23.2   Consent of Cooley LLP (included in Exhibit 5.1).
     
24.1   Power of Attorney (included on the signature page of the Registration Statement on Form S-1 (File No. 333-257810), filed with the Commission on July 9, 2021 and incorporated herein by reference).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Columbia, Maryland, on July 29, 2021.

 

  MAXCYTE, INC.

 

By:/s/ Doug Doerfler

Name:Doug Doerfler

Title:President and Chief Executive Officer

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

  Signature Title Date

 

  /s/ Doug Doerfler   President, Chief Executive Officer and Director   July 29, 2021
  Doug Doerfler   (Principal Executive Officer)    
           
  /s/ Amanda L. Murphy   Chief Financial Officer   July 29, 2021
  Amanda L. Murphy        
           
  /s/ Ron Holtz   Senior Vice President and Chief Accounting Officer   July 29, 2021
  Ron Holtz        
           
  *   Chairman of the Board of Directors   July 29, 2021
  J. Stark Thompson, PhD        
           
  *   Director   July 29, 2021
  Yasir Al-Wakeel, BM BCh        
           
  *   Director   July 29, 2021
  Will Brooke        
           
  *   Director   July 29, 2021
  Richard Douglas, PhD        
           
  *   Director   July 29, 2021
  Stanley C. Erck        
           
  *   Director   July 29, 2021
  Rekha Hemrajani        
           
  *   Director   July 29, 2021
  John Johnston        
           
  *   Director   July 29, 2021
  Art Mandell        

 

* /s/ Doug Doerfler        
  Doug Doerfler        

 

Attorney-in-fact